N2 members this message is courtesy of the Clinical Trials Transformation Initiative, who are hosting a webinar to identify best practices for conducting clinical trials with the new FDA guidance during the Covid-19 pandemic.
This week, stakeholders from across the clinical trials ecosystem submitted experiences and insights related to the FDA’s new guidance on the conduct of clinical trials of medical products during the current COVID-19 pandemic. The Clinical Trials Transformation Initiative (CTTI) collated the feedback – including insights on safety considerations, remote study visits, remote consent, consulting with IRBs, and more – and will share the findings and best practices via a webinar on Tuesday, March 31 at 11:15 a.m. EST.
M. Khair ElZarrad, FDA, CDER, will provide opening comments and a full discussion on the findings, along with detailed examples of best practices, will be presented by:
- David Borasky, WCG
- Sara Calvert, CTTI
- Cindy Geoghegan, Individual Patient Representative/Caregiver
- Colleen Rouse, Cleveland Clinic
- Pamela Tenaerts, CTTI
